{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"028-140-253-487-170","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"028-140-253-487-170"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11789,"type":"PATENT","title":"Newcastle University Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":9350,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8422,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: Newcastle Univ*. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1333
Search Applicants and Owners separately: Newcastle Univ*. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1333
expressing in a plurality of cells a recombinant nucleic acid molecule comprising a heterologous nucleotide sequence to be expressed, said sequence under the control of a regulatory sequence selected from the group consisting of:\n\n(a) regulatory sequences comprising the nucleotide sequence shown in SEQ ID NO: 1, as shown in SEQ ID NO: 2, as shown in SEQ ID NO: 3 or as shown in SEQ ID NO: 4;\n(b) regulatory sequences comprising the nucleotide sequence contained in the insertion of clone DSM 15111 and obtainable by amplification using two oligonucleotides having the sequences indicated under SEQ ID NO: 9 and SEQ ID NO: 10;\n(c) regulatory sequences comprising at least one nucleotide sequence of SEQ ID NO: 1 from position 1166 to 1746, from position 1166 to 2049, from position 1785 to 1843 or from position 1953 to 2775;\n(d) regulatory sequences comprising at least one nucleotide sequence of SEQ ID NO: 2 from position 529 to 1079, from position 529 to 1390, from position 1118 to 1175 or from position 1291 to 2137; regulatory sequences comprising a nucleotide sequence which is at least 75% identical to a sequence as defined in (a) to (d) or which comprises a nucleotide sequence which is at least 78% identical to the nucleotide sequence as shown in SEQ ID NO: 1 from position 1166 to 1746 or from position 1166 to 2049 or to the nucleotide sequence shown in SEQ ID NO: 2 from position 529 to 1079 or from position 529 to 1390, which comprises a nucleotide sequence which is at least 82% identical to the nucleotide sequence as shown in SEQ ID NO: 1 from position 1785 to 1843 or to the nucleotide sequence as shown in SEQ ID NO: 2 from position 1118 to 1175 or which comprises a nucleotide sequence which is at least 75% identical to the nucleotide sequence as shown in SEQ ID NO: 1 from position 1953 to 2775 or to the nucleotide sequence as shown in SEQ ID NO: 2 from position 1291 to 2137; and\n(f) regulatory sequences comprising a nucleotide sequence which hybridizes under stringent conditions with a complementary strand of the regulatory sequence as defined in (a) to (e) and which provides early, transient expression of a heterologous nucleotide sequence in proliferative neuronal determined cells; and\n
selecting cells which express a heterologous nucleotide sequence under the control of the regulatory sequence."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, which comprises in step (b) the detection of an expressed, heterologous marker or reporter gene."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein said regulatory sequence is of human, mouse or rat origin."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 2, wherein said heterologous nucleotide sequence to be expressed is a gene selected from the group consisting of a marker gene, a receptor gene, an anti-apoptotic gene, a determination/differentiation gene, a gene capable of inducing and/or directing neuronal migration or guidance, a gene encoding a tag, a gene encoding for a trophic factor, a gene encoding a surface protein, a gene encoding for a transcription factor ora gene encoding an enzyme, or wherein said nucleotide sequence to be expressed is an antisense sequence or encodes for a ribozyme or an inhibiting RNA molecule."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 4, wherein said marker or receptor gene is selected from the group consisting of GFP, EGFP, RFP, CFP, BFP, YFP, DsRed, f3-galactosidase, luciferase or chloramphenicol acetyltransferase."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 4, wherein said gene encoding a tag is selected from the group consisting of a His-Tag, glutathione, a Strep-tag, a Flag-tag, CBP, TAG-100, E2-tag and Z-tag."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 4, wherein said gene encoding a surface protein is CD24."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 4, wherein said gene encoding for a trophic factor is selected from the group consisting of NGF, BDNF, PDGF, NT-3, NT-4, NT-5, VEGF, PEDF, EGF, FGF, IGF, cardiotrophin, erythropoietin, leptin, LIF, and TGF."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 4, wherein said anti-apoptotic gene is selected from the group consisting of bc1-2, Brn-3a, PTEN and (an) anti-caspase(s)."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 4, wherein said determination/differentiation gene is the dopaminergic determination factor Nurr1."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 4, wherein said gene capable of inducing and/or directing neuronal migration or guidance is selected from the group consisting of netrin, neuropilin, CXCR4, SDF-1, DCC, slit, robo, a semaphorin, a plexin family member, and an ephrin family member."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 4, wherein said gene encoding a transcription factor is selected from the group consisting of NeuroD, BMP4, Nun 1 or ShcC."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 4, wherein said gene encoding an enzyme is CRE."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 4, wherein said heterologous nucleotide sequence to be expressed is an antisense sequence, or encodes for a ribozyme or an inhibiting RNA-molecule."],"number":14,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 14, wherein said inhibiting RNA is selected from the group consisting of RNAi, siRNA, shRNA and stRNA."],"number":15,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 2, wherein said recombinant nucleic acid molecule is further defined as a recombinant vector comprising said a regulatory sequence and heterologous nucleotide sequences to be expressed positioned under the control of said regulatory sequence."],"number":16,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 16, wherein said vector is further defined as a virus."],"number":17,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 16, wherein said vector is further defined as vector is suitable for gene therapy or vaccination with a nucleic acid molecule."],"number":18,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the regulatory sequence comprises the nucleotide sequence shown in SEQ ID NO: 1, as shown in SEQ ID NO: 2, as shown in SEQ ID NO: 3 or as shown in SEQ ID NO: 4."],"number":19,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the regulatory sequence comprises the nucleotide sequence contained in the insertion of clone DSM 15111 and obtainable by amplification using two oligonucleotides having the sequences indicated under SEQ ID NO: 9 and SEQ ID NO: 10."],"number":20,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the regulatory sequence comprises at least one nucleotide sequence of SEQ ID NO: 1 from position 1166 to 1746, from position 1166 to 2049, from position 1785 to 1843 or from position 1953 to 2775."],"number":21,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the regulatory sequence comprises at least one nucleotide sequence of SEQ ID NO: 2 from position 529 to 1079, from position 529 to 1390, from position 1118 to 1175 or from position 1291 to 2137."],"number":22,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the regulatory sequence comprises a nucleotide sequence which is at least 75% identical to the regulatory sequences set forth in SEQ ID NOs 1 through 4, or which comprises a nucleotide sequence which is at least 78% identical to the nucleotide sequence as shown in SEQ ID NO: 1 from position 1166 to 1746 or from position 1166 to 2049 or to the nucleotide sequence shown in SEQ ID NO: 2 from position 529 to 1079 or from position 529 to 1390, which comprises a nucleotide sequence which is at least 82% identical to the nucleotide sequence as shown in SEQ ID NO: 1 from position 1785 to 1843 or to the nucleotide sequence as shown in SEQ ID NO: 2 from position 1118 to 1175 or which comprises a nucleotide sequence which is at least 75% identical to the nucleotide sequence as shown in SEQ ID NO: 1 from position 1953 to 2775 or to the nucleotide sequence as shown in SEQ ID NO: 2 from position 1291 to 2137."],"number":23,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the regulatory sequence comprises a nucleotide sequence which hybridizes with a complementary strand of the regulatory sequence as defined in claim 22 under stringent conditions and which provides early, transient expression of a heterologous nucleotide sequence in proliferative neuronal determined cells."],"number":24,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}